Abstract
Major capsid protein (MCP) can be used as a subunit vaccine against largemouth bass virus (LMBV). However, subunit vaccines usually have low immunogenicity. Here, to identify the major immunogenicity determinant region of the MCP gene, we truncated the MCP of the LMBV gene into four parts ( MCP ‐ 1, MCP ‐ 2, MCP ‐ 3 and MCP ‐ 4 ). Enzyme‐linked immunosorbent assay (ELISA) was used to identify the antigenicity of these four truncated MCP proteins. Then, the highly antigenic truncated protein was modified with mannose and connected with functionalized single‐walled carbon nanotubes (SWCNTs) as carriers. Largemouth basses were immunized by bath immersion, challenged with LMBV on the 28th day after immunization and evaluated for related immune indicators. The results indicated that the MCP‐2 protein could induce a higher antibody titre than the other truncated MCP proteins. We found that the levels of immune‐related genes ( TNF‐α, CD40 , IgM , IFNγ and IL‐10 ) in the spleen and kidney were significantly increased in the MCP‐2 and MCP‐2‐Man groups. ELISA results showed that the antibody content in the serum increased significantly in the MCP‐2 group 7 days post‐vaccination and increased with days in all the vaccinated groups, with the highest observed on the 21st day. Notably, the MCP‐2‐Man vaccine (10 mg L −1 ) showed durability of immunoprotection efficacy that could protect largemouth basses from LMBV challenge, and the immune protection rate reached 78.94%. These results suggest that MCP‐2 might be the major immunogenicity determinant region of LMBV and that the mannose‐modified MCP‐2 vaccine can induce stronger adaptive immune responses.